Monday, September 15, 2025

Revive Expands Phase 3 COVID-19 Study To Asia Pacific Region, Canada

Revive Therapeutics (CSE: RVV) announced this morning that it is expanding its phase 3 clinical trials following the approval granted by the US Food and Drug Administration. The company is expanding its plans to include both Asia-Pacific Countries (APAC) as well as Canada.

The phase 3 trials, which consist of the company studying the use of Bucillamine in the treatment of mild-moderate COVID-19 and other infectious diseases, are currently expected to open for patient enrollment and dosing next month in September. Revive and its clinical trial partners are currently evaluating potential clinical sites, which includes the previously announced states of California, Florida, Arizona and Texas as well as in the additional US states and now Canada and the APAC region.

The announcement of the expansion of the clinical trial regions follows the announcement last week that the company has signed a memorandum of understanding with Attwill Medical Solutions Sterilflow, LP, the same firm utilized by Vaxart Inc (NASDAQ: VXRT) for its clinical stage oral COVID vaccine, as a resource for clinical packaging and distribution of the phase 3 clinical trial. Further vendor agreements are in the process of being finalized currently.

“With the approval from the FDA to conduct the Phase 3 clinical trial in COVID-19 and our progress that we have made to date, we are now establishing plans to complement and support our initiatives in the U.S. to include clinical sites in APAC and Canada.”

Michael Frank, CEO of Revive Therapeutics

The scientific rationale for the use of Bucillamine in the treatment of COVID-19, as well as the details of the phase 3 confirmatory clinical study, can be found here.

Revive Therapeutics last traded at $0.28 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

New Found Gold: The Strategic Maritime Resources Purchase

Amex Exploration: Revised Perron PEA Has INSANE Economics

Aris Mining: The Multi Billion Dollar Soto Norte PFS

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

Revive Therapeutics Provides Update On Current Psilocybin Programs

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its...

Tuesday, August 10, 2021, 08:36:06 AM

Revive Therapeutics Granted FDA Approval For Phase 3 Clinical Trial For Bucillamine In COVID-19 Treatment

It’s a big day for Revive Therapeutics (CSE: RVV) (OTC: RVVTF). The company announced this...

Friday, July 31, 2020, 09:16:29 AM

Havn Life to Supply Revive Therapeutics With Psychedelic Compounds

This morning Revive Therapeutics (CSE: RVV) announced they have signed a supply agreement with Havn...

Tuesday, October 20, 2020, 10:16:16 AM

Revive Therapeutics Director Signs Manufacturing Arrangement With Vaxart

It appears that Revive Therapeutics (CSE: RVV) has a budding superstar on its board of...

Thursday, July 2, 2020, 10:16:41 AM

Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19

Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered...

Monday, May 3, 2021, 09:24:15 AM